Related Experiment Videos
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem
Insights
Pseudomonas cepacia infections are increasing in cystic fibrosis patients, causing severe lung issues and difficult-to-treat infections. This highlights a critical challenge in managing this opportunistic pathogen in vulnerable populations.
Area of Science:
- Medical Microbiology
- Pulmonology
- Infectious Diseases
Background:
- Cystic fibrosis (CF) patients are susceptible to bacterial lung infections.
- Pseudomonas aeruginosa is a common CF pathogen, but Pseudomonas cepacia (now Burkholderia cepacia complex) is increasingly recognized.
- Understanding the epidemiology and clinical impact of P. cepacia in CF is crucial.
Purpose of the Study:
- To assess the changing prevalence of P. cepacia in CF patients.
- To compare the clinical outcomes of P. cepacia and P. aeruginosa infections.
- To highlight the challenges in treating P. cepacia infections in CF.
Main Methods:
- Retrospective analysis of P. cepacia and P. aeruginosa prevalence in CF patients from 1971 to 1981.
- Comparison of pulmonary function impairment between patients with P. cepacia and P. aeruginosa.
- Clinical case review of a severe P. cepacia-associated syndrome.
Main Results:
- P. cepacia prevalence rose from 10% to 18% between 1971 and 1981, while P. aeruginosa carriage remained high (70-80%).
- P. cepacia infection was associated with greater pulmonary function impairment compared to P. aeruginosa.
- A severe P. cepacia syndrome with high fever, respiratory failure, and leukocytosis occurred in 8 patients (62% fatality rate).
- P. cepacia strains showed uniform resistance to common antibiotics (e.g., aminoglycosides, ticarcillin, piperacillin), and ceftazidime was ineffective.
Conclusions:
- P. cepacia poses a significant and growing threat to cystic fibrosis patients.
- Treatment of P. cepacia infections in CF is challenging due to widespread antibiotic resistance.
- Prevention and effective treatment strategies for P. cepacia are urgently needed in CF care.
Abstract:
The prevalence of Pseudomonas cepacia infection increased from 10% in 1971 to 18% by 1981 in a population of approximately 500 patients with cystic fibrosis. Carriage of P. aeruginosa has remained unchanged at 70% to 80% over the same period. Patients infected with P. cepacia have greater impairment of pulmonary function than those with P. aeruginosa. A syndrome characterized by high fever, severe progressive respiratory failure, leukocytosis, and elevated erythrocyte sedimentation rate has occurred in eight patients over the past 3 years, with a 62% fatality rate. Because P. cepacia strains are uniformly resistant to ticarcillin, piperacillin, and aminoglycosides, and because ceftazidime is ineffective despite in vitro activity, treatment of these infections is very difficult. Prevention of acquisition and effective treatment of P. cepacia in patients with cystic fibrosis are now major clinical problems in our clinic.